Published in PLoS One on August 13, 2012
Targeting Hepatitis B Virus With CRISPR/Cas9. Mol Ther Nucleic Acids (2014) 1.33
Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog (2013) 1.04
Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics. Antiviral Res (2015) 0.94
Therapeutic strategies for a functional cure of chronic hepatitis B virus infection. Acta Pharm Sin B (2014) 0.89
Spinoculation Enhances HBV Infection in NTCP-Reconstituted Hepatocytes. PLoS One (2015) 0.85
Truncated active human matrix metalloproteinase-8 delivered by a chimeric adenovirus-hepatitis B virus vector ameliorates rat liver cirrhosis. PLoS One (2013) 0.84
DNA Polymerase κ Is a Key Cellular Factor for the Formation of Covalently Closed Circular DNA of Hepatitis B Virus. PLoS Pathog (2016) 0.80
Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg for screening of cccDNA modulators. Antiviral Res (2016) 0.76
Effect of mismatch repair on the mutation rate of bacteriophage ϕX174. Virus Evol (2015) 0.75
Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol (1967) 106.91
Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate. Cell (1982) 16.71
Hepatitis B virus biology. Microbiol Mol Biol Rev (2000) 7.58
Double-strand break end resection and repair pathway choice. Annu Rev Genet (2011) 7.31
Genome of hepatitis B virus: restriction enzyme cleavage and structure of DNA extracted from Dane particles. Proc Natl Acad Sci U S A (1975) 6.68
Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell (1986) 6.12
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med (2003) 5.97
High-level hepatitis B virus replication in transgenic mice. J Virol (1995) 5.81
Novel mechanism for reverse transcription in hepatitis B viruses. J Virol (1993) 4.47
Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J Virol (1990) 4.26
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology (2000) 3.58
Evidence that a capped oligoribonucleotide is the primer for duck hepatitis B virus plus-strand DNA synthesis. J Virol (1986) 3.46
Protein covalently bound to minus-strand DNA intermediates of duck hepatitis B virus. J Virol (1983) 3.35
Mutations affecting hepadnavirus plus-strand DNA synthesis dissociate primer cleavage from translocation and reveal the origin of linear viral DNA. J Virol (1991) 3.26
Hepadnavirus reverse transcription initiates within the stem-loop of the RNA packaging signal and employs a novel strand transfer. J Virol (1994) 2.98
In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology (1990) 2.76
Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology (2002) 2.54
Ku acts in a unique way at the mammalian telomere to prevent end joining. Genes Dev (2000) 2.38
Hepatitis B virus replication. World J Gastroenterol (2007) 2.30
Structural relationships between the surface antigens of ground squirrel hepatitis virus and human hepatitis B virus. J Virol (1980) 2.20
Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol (2001) 1.98
Nuclear import of hepatitis B virus capsids and release of the viral genome. Proc Natl Acad Sci U S A (2003) 1.93
Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation. J Virol (2007) 1.80
The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol (1995) 1.72
Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein. J Virol (2007) 1.51
Illegitimate replication of linear hepadnavirus DNA through nonhomologous recombination. J Virol (1995) 1.50
Covalently closed circular viral DNA formed from two types of linear DNA in woodchuck hepatitis virus-infected liver. J Virol (1996) 1.45
Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration. Proc Natl Acad Sci U S A (2004) 1.39
Conditional replication of duck hepatitis B virus in hepatoma cells. J Virol (2003) 1.39
Production and function of the cytoplasmic deproteinized relaxed circular DNA of hepadnaviruses. J Virol (2010) 1.33
Identification and characterization of avihepadnaviruses isolated from exotic anseriformes maintained in captivity. J Virol (2005) 1.26
Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays. Antiviral Res (2006) 1.22
Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. J Virol (2010) 1.18
Nuclear export and import of human hepatitis B virus capsid protein and particles. PLoS Pathog (2010) 1.18
Integration of hepadnavirus DNA in infected liver: evidence for a linear precursor. J Virol (1999) 1.17
Reasons to consider earlier treatment of chronic HBV infections. Gut (2011) 1.15
Intracellular transport of hepatitis B virus. World J Gastroenterol (2007) 1.14
Generation of covalently closed circular DNA of hepatitis B viruses via intracellular recycling is regulated in a virus specific manner. PLoS Pathog (2010) 1.13
Base pairing among three cis-acting sequences contributes to template switching during hepadnavirus reverse transcription. Proc Natl Acad Sci U S A (2003) 1.12
Nucleoporin 153 arrests the nuclear import of hepatitis B virus capsids in the nuclear basket. PLoS Pathog (2010) 1.04
Mechanism for CCC DNA synthesis in hepadnaviruses. PLoS One (2009) 0.88
Alpha interferon-induced antiviral response noncytolytically reduces replication defective adenovirus DNA in MDBK cells. Antiviral Res (2007) 0.79
miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol (2004) 6.44
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells. J Virol (2003) 4.06
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections. J Virol (2010) 3.10
Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology (2008) 3.00
Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J Virol (2010) 2.98
GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol (2005) 2.70
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov (2012) 2.47
Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J Virol (2007) 2.40
Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res (2010) 2.20
Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. J Proteome Res (2009) 2.20
Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J Virol (2008) 1.96
Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res (2006) 1.93
Replication of a cytopathic strain of bovine viral diarrhea virus activates PERK and induces endoplasmic reticulum stress-mediated apoptosis of MDBK cells. J Virol (2002) 1.93
Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation. J Virol (2007) 1.80
Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev (2009) 1.79
Preferential isolation of fragmented DNA enhances the detection of circulating mutated k-ras DNA. Clin Chem (2004) 1.78
Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. J Mol Diagn (2004) 1.62
SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology (2005) 1.55
Production and function of the cytoplasmic deproteinized relaxed circular DNA of hepadnaviruses. J Virol (2010) 1.33
Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J Virol (2007) 1.33
Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother (2012) 1.31
Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions. Antiviral Res (2013) 1.29
Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J Virol (2008) 1.28
Molecular virology of hepatitis B virus for clinicians. Clin Liver Dis (2007) 1.28
Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov (2013) 1.27
Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Res (2012) 1.27
A substituted tetrahydro-tetrazolo-pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion. Antimicrob Agents Chemother (2007) 1.27
Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays. Antiviral Res (2006) 1.22
Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein. PLoS Pathog (2013) 1.22
Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. J Virol (2010) 1.18
Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Res (2013) 1.16
N-linked glycosylation of the liver cancer biomarker GP73. J Cell Biochem (2008) 1.14
Chronic hepatitis B: what should be the goal for new therapies? Antiviral Res (2013) 1.12
Antiviral effect of interferon lambda against West Nile virus. Antiviral Res (2009) 1.12
Regulation of hepatitis B virus replication by the phosphatidylinositol 3-kinase-akt signal transduction pathway. J Virol (2007) 1.10
The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy. Antiviral Res (2012) 1.10
The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin. J Infect Dis (2011) 1.10
Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. Antiviral Res (2010) 1.09
Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells. J Virol (2010) 1.08
Antiviral activities of ISG20 in positive-strand RNA virus infections. Virology (2010) 1.08
Comparative proteomic analysis of de-N-glycosylated serum from hepatitis B carriers reveals polypeptides that correlate with disease status. Proteomics (2004) 1.06
Detection of mutated K-ras DNA in urine, plasma, and serum of patients with colorectal carcinoma or adenomatous polyps. Ann N Y Acad Sci (2008) 1.05
Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses. Antimicrob Agents Chemother (2009) 1.04
Interferon induction of IFITM proteins promotes infection by human coronavirus OC43. Proc Natl Acad Sci U S A (2014) 1.04
Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog (2013) 1.04
A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics (2003) 1.03
Stability and circularization of herpes simplex virus type 1 genomes in quiescently infected PC12 cultures. J Gen Virol (2002) 1.03
Inhibitors of endoplasmic reticulum alpha-glucosidases potently suppress hepatitis C virus virion assembly and release. Antimicrob Agents Chemother (2010) 1.03
Detection of clonally expanded hepatocytes in chimpanzees with chronic hepatitis B virus infection. J Virol (2009) 1.00
Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids. J Virol (2013) 0.99
Competitive inhibitor of cellular α-glucosidases protects mice from lethal dengue virus infection. Antiviral Res (2011) 0.99
Fucosylated glycoproteins as markers of liver disease. Dis Markers (2008) 0.98
Inhibition of host ER glucosidase activity prevents Golgi processing of virion-associated bovine viral diarrhea virus E2 glycoproteins and reduces infectivity of secreted virions. Virology (2002) 0.98
Transrenal DNA as a diagnostic tool: important technical notes. Ann N Y Acad Sci (2004) 0.97
Hepatitis B virus-mediated changes of apolipoprotein mRNA abundance in cultured hepatoma cells. J Virol (2003) 0.96
Glyco- and peptidomimetics from three-component Joullié-Ugi coupling show selective antiviral activity. J Am Chem Soc (2005) 0.95
A southern blot assay for detection of hepatitis B virus covalently closed circular DNA from cell cultures. Methods Mol Biol (2013) 0.93
Impact of the location of CpG methylation within the GSTP1 gene on its specificity as a DNA marker for hepatocellular carcinoma. PLoS One (2012) 0.92
Hepatitis B and hepatitis C virus replication upregulates serine protease inhibitor Kazal, resulting in cellular resistance to serine protease-dependent apoptosis. J Virol (2009) 0.92
Alkylated porphyrins have broad antiviral activity against hepadnaviruses, flaviviruses, filoviruses, and arenaviruses. Antimicrob Agents Chemother (2010) 0.92
Small molecule inhibitors of ER α-glucosidases are active against multiple hemorrhagic fever viruses. Antiviral Res (2013) 0.91
The liver of woodchucks chronically infected with the woodchuck hepatitis virus contains foci of virus core antigen-negative hepatocytes with both altered and normal morphology. Virology (2006) 0.91
Hepatitis B virus large and middle glycoproteins are degraded by a proteasome pathway in glucosidase-inhibited cells but not in cells with functional glucosidase enzyme. J Virol (2005) 0.90
Quantitative dynamics of hepatitis B basal core promoter and precore mutants before and after HBeAg seroconversion. J Hepatol (2011) 0.90
The amount of hepatocyte turnover that occurred during resolution of transient hepadnavirus infections was lower when virus replication was inhibited with entecavir. J Virol (2008) 0.90
Tumor-associated protein SPIK/TATI suppresses serine protease dependent cell apoptosis. Apoptosis (2008) 0.90
The alkylated imino sugar, n-(n-Nonyl)-deoxygalactonojirimycin, reduces the amount of hepatitis B virus nucleocapsid in tissue culture. J Virol (2003) 0.89